Bioplatforms Australia is proud to partner with Therapeutic Innovation Australia (TIA), Phenomics Australia, and ANSTO to support translational medical research through the Pipeline Accelerator voucher scheme. The initiative, launched by TIA, tackles the medical...
Illicit drug use poses a growing public health challenge, with increasingly potent and unpredictable substances circulating in the community. In recent years, new synthetic drugs and dangerous drug mixtures have become more common, increasing the risk of overdose and...
Australian researchers have achieved the most promising advance in brain cancer treatment in two decades, with a new clinical trial showing that a targeted drug can shrink previously incurable tumours by up to 90 per cent. As reported by Natasha Robinson in The...
Bioplatforms Australia, Australian BioCommons, and the European Molecular Biology Laboratory (EMBL) are deepening their long-standing collaboration in life science research, focusing on biological data, bioinformatics, and the growing role of artificial intelligence...
Key Points 1. The aim of this Voucher Scheme is to enable projects addressing significant scientific challenges using synthetic biology capabilities at NCRIS SynBio and NCRIS Partner facilities. 2. Applications for a Primary Voucher will include a Lead Provider from...
Therapeutic Innovation Australia (TIA), in partnership with Phenomics Australia, Bioplatforms Australia and ANSTO’s National Deuteration Facility, is thrilled to announce the successful recipients of the Pipeline Accelerator 2024-25 (Round 2). ...
